Lantheus Holdings, Inc.

LNTH Healthcare Drug Manufacturers Specialty & Generic

Lantheus Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, up 0.50% from fiscal 2024. In the quarter to June 2026, revenue grew 2.68%, EPS was flat, free cash flow grew 13.6% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years.

99.70 0.29 −0.29%
Market cap
$6.5B
P/E
23.7×
Fwd P/E
25.3×
Dividend yield
—
F-score
5/9
Altman Z
4.25
Beneish M
−2.23
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

20.93 19.35 18.02 26.35
P/S ratio
2.26 2.91 3.18 4.64
P/FCF ratio
8.14 12.69 12.85 18.40
P/Operating CF
32.75 49.81 39.24 78.40
P/B ratio
3.08 4.12 4.05 5.51
EV/Sales
2.38 3.05 3.22 4.63
EV/EBITDA
8.73 12.20 13.33 18.23
EV/FCF
8.58 13.28 13.04 18.35
Current Ratio
2.67 2.70 2.83 3.06
Net Debt/EBITDA
2.87 2.08 0.68 (0.18)
Debt/Equity
0.51 0.52 0.47 0.44
Earnings Yield
4.78% 5.17% 5.55% 3.79%
Free Cash Flow Yield
12.29% 7.88% 7.78% 5.43%
Free Cash Flow per Share
1.41 1.21 1.96 1.38
Book value per Share
16.65 16.15 18.73 20.13
Free Cash Flow
94.67 81.39 126.90 89.87
EV/EBIT
10.46 15.13 17.17 23.84
Other line items

Show all line items

Columns are period end dates